MX2021015897A - Factor viii recombinante-fc para el tratamiento de la hemofilia y la densidad mineral osea baja. - Google Patents
Factor viii recombinante-fc para el tratamiento de la hemofilia y la densidad mineral osea baja.Info
- Publication number
- MX2021015897A MX2021015897A MX2021015897A MX2021015897A MX2021015897A MX 2021015897 A MX2021015897 A MX 2021015897A MX 2021015897 A MX2021015897 A MX 2021015897A MX 2021015897 A MX2021015897 A MX 2021015897A MX 2021015897 A MX2021015897 A MX 2021015897A
- Authority
- MX
- Mexico
- Prior art keywords
- bone mineral
- mineral density
- low bone
- factor viii
- recombinant factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se divulgan en el presente documento métodos de tratamiento de sujetos con hemofilia y densidad mineral ósea baja (DMO), con una proteína quimérica que comprende un factor de coagulación y un dominio Fc. En ciertas modalidades, la proteína quimérica es rFVIIIFc. En ciertas modalidades, el sujeto a tratar tiene hemofilia A.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962863831P | 2019-06-19 | 2019-06-19 | |
US202062968785P | 2020-01-31 | 2020-01-31 | |
PCT/US2020/038444 WO2020257462A1 (en) | 2019-06-19 | 2020-06-18 | Recombinant factor viii-fc for treating hemophilia and low bone mineral density |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021015897A true MX2021015897A (es) | 2022-04-18 |
Family
ID=71465486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021015897A MX2021015897A (es) | 2019-06-19 | 2020-06-18 | Factor viii recombinante-fc para el tratamiento de la hemofilia y la densidad mineral osea baja. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220233650A1 (es) |
EP (1) | EP3986444A1 (es) |
JP (1) | JP2022537200A (es) |
KR (1) | KR20220024628A (es) |
CN (1) | CN114007637A (es) |
AU (1) | AU2020298233A1 (es) |
BR (1) | BR112021025426A2 (es) |
CA (1) | CA3144630A1 (es) |
CO (1) | CO2021016718A2 (es) |
IL (1) | IL289086A (es) |
MX (1) | MX2021015897A (es) |
TW (1) | TW202115127A (es) |
WO (1) | WO2020257462A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL309309A (en) * | 2021-06-23 | 2024-02-01 | Bioverativ Therapeutics Inc | Formulations of factor VIII chimeric proteins and uses thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1341174C (en) | 1985-04-12 | 2001-01-30 | John J. Toole Jr. | Procoagulant proteins derived from factor viii: c |
WO1987004187A1 (en) | 1986-01-03 | 1987-07-16 | Genetics Institute, Inc. | METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS |
US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US5610278A (en) | 1986-06-24 | 1997-03-11 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US5171844A (en) | 1987-06-12 | 1992-12-15 | Gist-Brocades N.W. | Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
BR112012013502A2 (pt) | 2009-12-06 | 2017-01-10 | Biogen Idec Hemophilia Inc | "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos". |
EP3513804B1 (en) | 2011-07-08 | 2022-03-23 | Bioverativ Therapeutics Inc. | Factor viii chimeric and hybrid polypeptides, and methods of use thereof |
CN104254614A (zh) | 2012-01-12 | 2014-12-31 | 比奥根艾迪克Ma公司 | 降低经受因子viii疗法的个体中针对因子viii的免疫原性的方法 |
KR102097263B1 (ko) | 2012-02-15 | 2020-04-06 | 바이오버라티브 테라퓨틱스 인크. | Viii 인자 조성물 및 이를 제조하고 사용하는 방법 |
SI2882450T1 (sl) * | 2012-07-11 | 2020-02-28 | Bioverativ Therapeutics Inc. | Kompleks faktorja VIII z XTEN in s proteinom von Willebrandovega faktorja in njegove uporabe |
US9623088B2 (en) | 2013-03-15 | 2017-04-18 | Bioverativ Therapeutics Inc. | Factor VIII polypeptide formulations |
PL4176894T3 (pl) | 2014-01-10 | 2024-07-22 | Bioverativ Therapeutics Inc. | Białka chimeryczne czynnika VIII i ich zastosowania |
DK3137506T5 (da) * | 2014-05-02 | 2024-10-14 | Momenta Pharmaceuticals Inc | Sammensætninger og fremgangsmåder relateret til genmanipulerede fc-konstrukter |
-
2020
- 2020-06-18 MX MX2021015897A patent/MX2021015897A/es unknown
- 2020-06-18 CN CN202080044418.6A patent/CN114007637A/zh active Pending
- 2020-06-18 KR KR1020227001588A patent/KR20220024628A/ko not_active Application Discontinuation
- 2020-06-18 AU AU2020298233A patent/AU2020298233A1/en active Pending
- 2020-06-18 CA CA3144630A patent/CA3144630A1/en active Pending
- 2020-06-18 WO PCT/US2020/038444 patent/WO2020257462A1/en active Application Filing
- 2020-06-18 EP EP20736890.3A patent/EP3986444A1/en active Pending
- 2020-06-18 TW TW109120602A patent/TW202115127A/zh unknown
- 2020-06-18 BR BR112021025426A patent/BR112021025426A2/pt unknown
- 2020-06-18 US US17/618,808 patent/US20220233650A1/en active Pending
- 2020-06-18 JP JP2021575272A patent/JP2022537200A/ja active Pending
-
2021
- 2021-12-09 CO CONC2021/0016718A patent/CO2021016718A2/es unknown
- 2021-12-16 IL IL289086A patent/IL289086A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020298233A1 (en) | 2022-01-20 |
CA3144630A1 (en) | 2020-12-24 |
WO2020257462A1 (en) | 2020-12-24 |
IL289086A (en) | 2022-02-01 |
EP3986444A1 (en) | 2022-04-27 |
KR20220024628A (ko) | 2022-03-03 |
WO2020257462A9 (en) | 2021-02-18 |
TW202115127A (zh) | 2021-04-16 |
CO2021016718A2 (es) | 2022-01-17 |
BR112021025426A2 (pt) | 2022-06-21 |
JP2022537200A (ja) | 2022-08-24 |
CN114007637A (zh) | 2022-02-01 |
US20220233650A1 (en) | 2022-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021010528A (es) | Metodos y composiciones para el tratamiento de las ulceras. | |
PH12019502661A1 (en) | Articles of manufacture and methods for treatment using adoptive cell therapy | |
GB2535937A (en) | Methods and compositions for modulating the immune system with Arginase I | |
WO2018068008A8 (en) | T cells expressing membrane-anchored il-12 for the treatment of cancer | |
NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
TW200730624A (en) | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 | |
EA201692200A1 (ru) | Комбинация леналидомида и полипептидной конструкции и ее применение | |
MX2010008206A (es) | Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf. | |
MY193211A (en) | Gla domains as targeting agents | |
WO2015067755A3 (en) | Novel methods and antibodies for treating coagulapathy | |
MX2022009100A (es) | Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer. | |
MX2015010404A (es) | Composiciones y metodos para tratamiento y reparacion de tendones. | |
MX2019005693A (es) | Factor viii direccionado a los globulos rojos y metodo para su uso. | |
MX2021015897A (es) | Factor viii recombinante-fc para el tratamiento de la hemofilia y la densidad mineral osea baja. | |
MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
MX2020010932A (es) | Enzimas quinureninasa humanas y sus usos. | |
MX2015010833A (es) | Tratamiento de la enfermedad del injerto contra el huesped en pacientes de trasplante. | |
MX2015013092A (es) | Modificación y nuevas composiciones de proteínas secretoglobinas de humano. | |
EA202091891A1 (ru) | Ингибитор гремлина-1 для лечения перелома кости или дефекта кости | |
MX2019006444A (es) | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. | |
MX2017014743A (es) | Metodo para reducir o inactivar contenido viral o microbiano en los procesos para la fabricacion de pancreatina. | |
PH12021550417A1 (en) | Compositions and methods for controlled ovarian stimulation | |
ATE445408T1 (de) | Verwendung von prolactin in der prophylaktischen krebstherapie | |
PH12014501044B1 (en) | Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells | |
MX2011005651A (es) | Metodos para el diagnostico y tratamiento de heridas y analisis con marcadores electricos para el pronostico de las heridas. |